

Pressmeddelande

Xintela AB (publ)
556780-3480
2021-03-19



Xintela gets tissue establishment license

Lund, Sweden, 19 March 2021 - Xintela announces today that the company has received a tissue establishment license from the Swedish Medical Products Agency for handling human tissues and cells for manufacturing medicinal products.

In order to conduct activities that use human tissues and cells for the manufacture of medicinal products, a tissue establishment license is required. After an inspection by the Medical Products Agency, Xintela has now been granted a tissue establishment license. This means that Xintela meets the requirements of quality and safety and complies with the relevant regulations.

This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the below contact, for publication at 13:30 CET on the 19th of March, 2021.

Xintela AB (publ)

Evvy Lundgren-Åkerlund, CEO

Tel: +46 46 275 65 00

Email: evvy@xintela.se

Medicon Village

223 81 Lund, Sweden

www.xintela.se

About Xintela

Xintela develops innovative and patent protected cell therapies and targeted cancer therapies based on the marker technology platform XINMARK®. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to select and quality assure stem cells (XSTEM®) to develop stem cell therapies for diseases that today lack efficient treatment options, including the joint disease osteoarthritis (OA). Xintela has built an in-house GMP-facility for manufacturing of stem cell products and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.